{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:25:04Z","timestamp":1768829104144,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ejca.2013.02.027","type":"journal-article","created":{"date-parts":[[2013,3,27]],"date-time":"2013-03-27T18:38:00Z","timestamp":1364409480000},"page":"2284-2293","source":"Crossref","is-referenced-by-count":71,"title":["Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin\/cyclophosphamide (EC)\u00b1bevacizumab \u2013 Results of the randomised GeparQuinto study (GBG 44)"],"prefix":"10.1016","volume":"49","clinical-trial-number":[{"clinical-trial-number":"2006-005834-19","registry":"10.18810\/euctr"}],"author":[{"given":"Jens","family":"Huober","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Hanusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahdi","family":"Rezai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Eidtmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kornelia","family":"Kittel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rn","family":"Hilfrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Schwedler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens-Uwe","family":"Blohmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Tesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelia","family":"H\u00f6\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherko","family":"K\u00fcmmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Mau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Jackisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariba","family":"Khandan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serban Dan","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Krabisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibylle","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Nekljudova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Untch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunter von","family":"Minckwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2013.02.027_b0005","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes \u2013 dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2013.02.027_b0010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1159\/000335347","article-title":"Neoadjuvant therapy \u2013 what have we achieved in the last 20years","volume":"6","author":"Huober","year":"2011","journal-title":"Breast Care"},{"key":"10.1016\/j.ejca.2013.02.027_b0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-010-1103-9","article-title":"Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study","volume":"124","author":"Huober","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2013.02.027_b0020","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2009.23.8303","article-title":"Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study","volume":"28","author":"von Minckwitz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.02.027_b0025","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/jnci\/djn085","article-title":"Neoadjuvant vinorelbine\u2013capecitabine versus docetaxel\u2013doxorubicin\u2013cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial","volume":"100","author":"von Minckwitz","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2013.02.027_b0030","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejca.2013.02.027_b0035","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/sj.onc.1208304","article-title":"PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas","volume":"24","author":"Lee","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2013.02.027_b0040","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signalling network for cancer therapy","volume":"27","author":"Bernstam","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.02.027_b0045","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1517\/14728222.2011.575362","article-title":"mTOR inhibition in breast cancer: unravelling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy","volume":"15","author":"O\u2019Regan","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.ejca.2013.02.027_b0050","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"MTOR and cancer: insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat Rev"},{"key":"10.1016\/j.ejca.2013.02.027_b0055","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1634\/theoncologist.2010-0402","article-title":"Targeting the phosphatidylinositol 3-kinase signalling pathway in breast cancer","volume":"16","author":"Hernandez-Aya","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2013.02.027_b0060","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.02.027_b0065","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2013.02.027_b0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2013.02.027_b0075","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND. 163","volume":"27","author":"Ellard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.02.027_b0080","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1158\/1078-0432.CCR-04-0361","article-title":"Targeting the mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells","volume":"10","author":"Mondesire","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2013.02.027_b0085","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/CAD.0b013e3283400a20","article-title":"Evaluation of the mTOR inhibitor, everolimus in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo","volume":"22","author":"O\u2019Reilly","year":"2011","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2013.02.027_b0090","first-page":"2713","article-title":"The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro","volume":"31","author":"Liu","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2013.02.027_b0095","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2013.02.027_b0100","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Tamrad: a GINECO randomized trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients with hormone-receptor positive, HER2 negative metastatic breast cancer with prior exposure to aromatase inhibitors","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.02.027_b0105","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","article-title":"Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy","volume":"29","author":"Morrow","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.02.027_b0110","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1200\/JCO.2009.27.8549","article-title":"Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab","volume":"28","author":"Andre","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2013.02.027_b0115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","article-title":"Bevacizumab in combination with neoadjuvant chemotherapy for breast cancer \u2013 the GEPARQUINTO study (GBG 44)","volume":"366","author":"von Minckwitz","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejca.2013.02.027_b0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","article-title":"Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial","volume":"13","author":"Untch","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2013.02.027_b0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/annonc\/mdq350","article-title":"Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial","volume":"22","author":"von Minckwitz","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2013.02.027_b0130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bjc.6604851","article-title":"Safety and pharmacokinetics of paclitaxel and the mTOR inhibitor everolimus in advanced solid tumors","volume":"100","author":"Campone","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2013.02.027_b0135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-010-1260-x","article-title":"Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer","volume":"125","author":"Jersusalem","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2013.02.027_b0140","article-title":"Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) in women with triple receptor-negative breast cancer","volume":"29","author":"Gonzalez-Angulo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ejca.2013.02.027_b0145","first-page":"5s","article-title":"Everolimus with paclitaxel plus bevcizumab as first-line therapy for HER2 negative metastatic breast cancer(MBC): a randomized, double blind, placebo controlled phase II trial of the Sarah Cannon Research Institute (SCRI)","volume":"30","author":"Yardley","year":"2012","journal-title":"J Clin Oncol"},{"issue":"24 Suppl.","key":"10.1016\/j.ejca.2013.02.027_b0150","article-title":"Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients \u2013 results of the GeparTrio trial","volume":"71","author":"von Minckwitz","year":"2011","journal-title":"Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913001597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913001597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T17:55:17Z","timestamp":1539798917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913001597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0959804913001597"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.02.027","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}